Evidence map›Paper›PMID 23118907›Full record

ArticlePloS one2012

Plasmodium falciparum field isolates from South America use an atypical red blood cell invasion pathway associated with invasion ligand polymorphisms.

Mary Lopez-Perez, Elizabeth Villasis, Ricardo L D Machado, Marinete M Póvoa, Joseph M Vinetz, Silvia Blair, Dionicia Gamboa, Sara Lustigman

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 36 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Phenotypic characterization of GhanaianFrontiers in immunology · 2022
    Article
  6. Short-term cryopreservation and thawing have minimal effects onFrontiers in cellular and infection microbiology · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Blockade ofExperimental and therapeutic medicine · 2015
    Article
  16. Article
  17. Mechanisms of cellular invasion by intracellular parasites.Cellular and molecular life sciences : CMLS · 2014
    Review
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 4 countries.

Mary Lopez-PerezMolecular Parasitology, Lindsley F Kimball Research Institute, New York Blood Center, New York City, New York, United States of America.
Elizabeth Villasis
Ricardo L D Machado
Marinete M Póvoa
Joseph M Vinetz
Silvia Blair
Dionicia Gamboa
Sara Lustigman
Universidad Peruana Cayetano Heredia · PEInstituto Evandro Chagas · BRNew York Blood Center · USUniversidad de Antioquia · CO

Funding

Sugar-feeding behavior of the malaria vector Nyssorhynchus darlingi and development of effective attractive toxic sugar baits (ATSB) to increase intervention success in PeruU19AI089681 · NIAID · YALE UNIVERSITY · PI GAZZINELLI, RICARDO TOSTES · 2010 to 2023
$20.1M
Patient-Oriented Research in Tropical Infectious DiseasesK24AI068903 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI VINETZ, JOSEPH M. · 2006 to 2015
$1.5M
Malaria Invasion Via Glycophorin B in Brazilian IsolatesR03TW007349 · FIC · NEW YORK BLOOD CENTER · PI LUSTIGMAN, SARA · 2005 to 2007
$106k
FIC NIH HHS R03 TW007349FIC NIH HHS R03TW007349NIAID NIH HHS K24 AI068903NIAID NIH HHS U19 AI089681NIAID NIH HHS U19AI089681
6 · The paper itself

Abstract

Studies of Plasmodium falciparum invasion pathways in field isolates have been limited. Red blood cell (RBC) invasion is a complex process involving two invasion protein families; Erythrocyte Binding-Like (EBL) and the Reticulocyte Binding-Like (PfRh) proteins, which are polymorphic and not fully characterized in field isolates. To determine the various P. falciparum invasion pathways used by parasite isolates from South America, we studied the invasion phenotypes in three regions: Colombia, Peru and Brazil. Additionally, polymorphisms in three members of the EBL (EBA-181, EBA-175 and EBL-1) and five members of the PfRh (PfRh1, PfRh2a, PfRh2b, PfRh4, PfRh5) families were determined. We found that most P. falciparum field isolates from Colombia and Peru invade RBCs through an atypical invasion pathway phenotypically characterized as resistant to all enzyme treatments (NrTrCr). Moreover, the invasion pathways and the ligand polymorphisms differed substantially among the Colombian and Brazilian isolates while the Peruvian isolates represent an amalgam of those present in the Colombian and Brazilian field isolates. The NrTrCr invasion profile was associated with the presence of the PfRh2a pepC variant, the PfRh5 variant 1 and EBA-181 RVNKN variant. The ebl and Pfrh expression levels in a field isolate displaying the NrTrCr profile also pointed to PfRh2a, PfRh5 and EBA-181 as being possibly the major players in this invasion pathway. Notably, our studies demonstrate the uniqueness of the Peruvian P. falciparum field isolates in terms of their invasion profiles and ligand polymorphisms, and present a unique opportunity for studying the ability of P. falciparum parasites to expand their invasion repertoire after being reintroduced to human populations. The present study is directly relevant to asexual blood stage vaccine design focused on invasion pathway proteins, suggesting that regional invasion variants and global geographical variation are likely to preclude a simple one size fits all type of vaccine.

Indexed as

ErythrocytesMalaria, FalciparumPlasmodium falciparumProtozoan ProteinsAnimalsHumansLigandsMalaria VaccinesPhenotypePolymorphism, GeneticReticulocytesSouth AmericaLigandsMalaria VaccinesProtozoan Proteins

Identifiers

PMID23118907
PMCPMC3485327
OpenAlexW2033607108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.